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abstract
PURPOSE Capivasertib is a pan-AKT inhibitor. Preclinical data indicate activity in metastatic castration-resistant
prostate cancer (mCRPC) and synergism with docetaxel.
PATIENTS AND METHODS ProCAID was a placebo controlled randomized phase II trial in mCRPC. Patients
received up to ten 21-day cycles of docetaxel (75mg/m2 intravenous, day 1) and prednisolone (5 mg twice daily,
oral, day 1-21) and were randomly assigned (1:1) to oral capivasertib (320 mg twice daily, 4 days on/3 days off,
from day 2 each cycle), or placebo, until disease progression. Treatment allocation used minimization factors:
bone metastases; visceral metastases; investigational site; and prior abiraterone or enzalutamide. The primary
objective, by intention to treat, determined if the addition of capivasertib prolonged a composite progression-free
survival (cPFS) end point that included prostate-specific antigen progression events. cPFS and overall survival
(OS) were also assessed by composite biomarker subgroup for PI3K/AKT/PTEN pathway activation status.
RESULTS One hundred and fifty patients were enrolled. Median cPFS was 7.03 (95% CI, 6.28 to 8.25) and
6.70months (95%CI, 5.52 to 7.36) with capivasertib and placebo respectively (hazard ratio [HR], 0.92; 80%CI,
0.73 to 1.16; one-sided P 5 .32). Median OS was 31.15 (95% CI, 20.07 to not reached) and 20.27 months
(95%CI, 17.51 to 24.18), respectively (HR, 0.54; 95%CI, 0.34 to 0.88; two-sided P5 .01). cPFS and OS results
were consistent irrespective of PI3K/AKT/PTEN pathway activation status. Grade III-IV adverse events were
equivalent between arms (62.2%). The most common adverse events of any grade deemed related to cap-
ivasertib were diarrhea, fatigue, nausea, and rash.
CONCLUSION The addition of capivasertib to chemotherapy did not extend cPFS in mCRPC irrespective of PI3K/
AKT/PTEN pathway activation status. The observed OS result (a secondary end point) will require prospective
validation in future studies to address potential for bias.
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INTRODUCTION
Hormone-sensitive metastatic prostate cancer is usually
responsive to androgen-deprivation therapy in docetaxel
or hormonal-therapy combinations.1-3 However subse-
quent progression to metastatic castration-resistant
prostate cancer (mCRPC) is almost inevitable at a
median of about one year.4
Overall survival (OS) benefit exists for several
mCRPC treatment options, including chemotherapy
(docetaxel and cabazitaxel), hormonal therapy
(abiraterone and enzalutamide), radium-223 and
sipuleucel-T.2 Although docetaxel for mCRPC im-
proves survival, pain, and quality of life, median
survival in phase III studies was only 17-19
months.5,6 No therapy has demonstrated superior
efficacy against, or combined with, docetaxel for
mCRPC. Most patients develop docetaxel resistance
during, or soon after, completion. For example, in a
trial of cabazitaxel following prior docetaxel, 28%-
30% experienced disease progression during
docetaxel and 42%-48% within 3 months.7
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PI3K/AKT/PTEN pathway activation in prostate cancer is
associated with negative clinical outcomes, including
castration resistance, chemoresistance or radioresistance,
metastasis, and postsurgical recurrence. Approximately
half of mCRPCs exhibit functional PTEN loss, and data
support PI3K/AKT/PTEN pathway activation as a relevant
therapeutic target in virtually all cases.8-11
Capivasertib (AZD5363) is an AKT1, 2, and 3 kinase in-
hibitor. It also inhibits protein kinase A and, with lower
potency, Rho-associated protein kinases (ROCK1 and 2).
Preclinical data, including prostate cancer models, indicate
reduced AKT substrate phosphorylation (PRAS40 and
GSK3b) and cell proliferation. Capivasertib also enhanced
docetaxel efficacy in breast cancer xenografts.12,13 Mono-
therapy trials demonstrated acceptable safety and phar-
macodynamic target modulation in tumors. Tumor size
reductions occurred in 46% and 56% of PIK3CA-mutated
breast and gynecological cancers respectively.14 Clinical
activity was also demonstrated in AKT1-mutant solid cancers,
including estrogen receptor (ER)-positive breast cancer.15
The phase Ib part of ProCAID established a recommended
phase II dose for capivasertib combined with docetaxel and
prednisolone (DP) in mCRPC.16 Consistent with mono-
therapy, the most common high-grade, capivasertib-
related symptomatic adverse events were rash and diar-
rhea. Transient hyperglycemia occurred in all patients but
was self-limiting. We hypothesized that capivasertib pro-
longs progression-free survival (PFS) when combined with
DP for mCRPC. The phase II part of ProCAID, reported
here, tested this.
METHODS
Study Design and Participants
ProCAID was an investigator-initiated, multicenter, ran-
domized, double-blind, phase II, placebo-controlled trial.
Patient eligibility criteria (Data Supplement, online only)
included $ 18 years, Eastern Cooperative Oncology Group
(ECOG) performance status 0-1, suitable for DP and with
progressive mCRPC. There were no restrictions on prior
hormonal therapies (eg, abiraterone and enzalutamide).
Exclusion criteria included previous chemotherapy for
mCRPC and diabetes mellitus requiring insulin or $ 2 oral
hypoglycemic medications. The Protocol (online only) was
amended during recruitment to permit prior docetaxel
chemotherapy for hormone-sensitive disease.
The study was in accordance with the Declaration of
Helsinki and Good Clinical Practice guidelines, and ap-
proved by West London & GTAC Research Ethics Com-
mittee (13/LO/1691). All patients provided written informed
consent.
Procedures
Patients were randomly assigned (1:1), with a minimi-
zation algorithm incorporating a 20% random component,
to either capivasertib or matched placebo combined with
DP. Stratification occurred for presence of bone metas-
tases, visceral (nonlymph node) disease, prior use of
abiraterone or enzalutamide, and investigational site.
Capivasertib and placebo were provided by AstraZeneca
(Cambridge, United Kingdom).
Patients received up to ten 21-day DP cycles (docetaxel
75 mg/m2, intravenous, day 1; prednisolone, 5 mg twice
daily, or 10 mg once daily, orally, days 1-21) with dexa-
methasone premedication (8 mg, orally, 12, 3 and 1 hours
predocetaxel, or similar) and antiemetic prophylaxis per
local practice. Patients also received either capivasertib, or
matched placebo, 320 mg orally, twice daily, on a 4 days
on/3 days off continuous schedule, commencing cycle one,
day 2, until disease progression.16 Dose modifications and
delays were permitted for hematological and non-
hematological toxicities within the Protocol.
Patients discontinued study treatment for disease progres-
sion by PCWG2 criteria (any of prostate-specific antigen
CONTEXT
Key Objective
To determine if the addition of the AKT inhibitor capivasertib to docetaxel chemotherapy improves progression-free survival
in patients with metastatic castration-resistant prostate cancer.
Knowledge Generated
In this phase II trial, the primary end point of progression-free survival was not extended by the addition of capivasertib to
chemotherapy, irrespective of biomarker status for the PI3K/AKT/PTEN signaling pathway. We did find that overall
survival, which was a secondary end point, was longer in patients who received the combination compared with
chemotherapy alone.
Relevance
Based on the primary end point, the addition of capivasertib to chemotherapy was not supported in this trial. The observed
overall survival extension would require prospective validation to exclude the potential for bias to have impacted on this
finding and the relative data maturity for this end point at the point of this primary analysis.
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[PSA] progression, radiological progression, or unequivocal
clinical progression) or need for new antiprostate cancer
systemic therapy or development of unacceptable toxicities,
loss to follow-up, or withdrawal of consent.17
PSA level was taken at baseline and every 21 days until
disease progression. Radiological disease evaluation was
via cross-sectional imaging of the chest, abdomen, and
pelvis, and bone scan, at baseline and subsequently as
clinically indicated according to local standards of care
(rather than prespecified intervals). Archival formalin-fixed
paraffin-embedded tumor tissue (diagnostic samples prior
to any cancer treatment), and baseline blood samples,
were taken for translational end points. Patients were
reviewed on day 1 of treatment cycles, and then 6 weekly
until disease progression, and then for survival status only.
A composite biomarker for PI3K/AKT/PTEN pathway acti-
vation status was prospectively defined for exploratory
analysis (Data Supplement). The biomarker population
included patients in the intent-to-treat (ITT) population with
at least one available result from either tumor tissue or
baseline plasma circulating tumor DNA (ctDNA). Patients
were biomarker-positive if PTEN deficiency was identified
by immunohistochemistry (IHC) of tumor tissue and/or an
eligible alteration was detected in PIK3CA, PTEN, or AKT1
by next-generation sequencing (NGS) of either tumor tissue
or baseline plasma ctDNA.
Outcomes
The primary outcome was investigator-assessed composite
PFS, calculated as time from random assignment to dis-
ease progression (any of PSA progression [PCWG217], soft
tissue disease progression [RECIST v1.118], bone metas-
tases progression [PCWG217], unequivocal clinical pro-
gression, and commencement of new antiprostate cancer
systemic therapy) or death. Secondary outcomes included
OS (time from random assignment to death) PFS excluding
PSA progression alone, PSA-based PFS (PSA progression or
death counting as events), PSA response (PCWG217), bone
pain changes (Brief Pain Inventory), and safety (Common
Terminology Criteria for Adverse Events [CTCAE] v4.03).
Statistical Analysis
Statistical analyses were prespecified within an a priori
statistical analysis plan. ProCAID was designed to detect
50% improvement in median composite PFS, from 6
(placebo) to 9 months (capivasertib) with 90% power and
20% one-sided level of statistical significance, requiring
111 events in 132 patients with 18-month accrual and 12-
month follow-up.19 To account for patients lost to follow-up
or nonevaluable, the protocol allowed for sample size in-
flation by 10% to 150 randomly assigned patients. Efficacy
analyses (except biomarker analyses) were conducted in
the ITT population comprising all randomly assigned pa-
tients. The safety population included all randomly
assigned patients who received any dose of docetaxel,
prednisolone, capivasertib, or placebo.
PFS (primary end point) was compared between study
arms by Cox proportional hazards model adjusting for
random assignment stratifications. The adjusted P-value
and hazard ratio (HR) with 80% CI was determined with
Kaplan-Meier methods to describe the data. Secondary
analyses of the primary end point included a test for in-
teraction, to assess whether study arm effect depended on
factors in the random assignment stratification (using forest
plots), and further subgroup analyses of baseline and
demographic characteristics. Sensitivity analyses of the
primary end point included unadjusted logrank testing for
difference in study arms, post hoc exploratory analysis
excluding initiation of new anticancer treatment as events,
proportional hazards assumptions checked using log cu-
mulative hazards, Schoenfeld’s global test, and time-
varying covariate analysis. OS and other PFS time to
event end points were analyzed using the same approach
as PFS.
Analysis of effect of biomarker status was planned pro-
spectively with subgroup analyses for PFS and OS by PI3K/
AKT/PTEN pathway alteration by Cox model using a similar
approach to the exploration of minimization factors of the
primary end point.
PSA response was compared between arms using logistic
regression adjusted for minimization factors, percentage
change at 12 weeks, and best response, displayed by
waterfall plot. Area under the curve to cycle 5 (Brief Pain
Inventory) was used to summarize average bone pain.
Worst adverse event grade for each patient was compared
between arms by the Mann-Whitney U test. Other displays
of safety data were by summary and descriptive statistics.
Except for the primary analysis described above, all sta-
tistical analyses were evaluated with two-sided 95% CIs, P-
values, and 5% significance. Analyses were performed
using STATA (version 16.0; College Station, TX) and SAS
(version 9.4; Cary, NC).
This study was overseen by an independent data monitoring
committee (IDMC) and registered with ClinicalTrials.gov
(ClinicalTrials.gov identifier: NCT02121639).
RESULTS
A total of three hundred ninety-nine patients were screened
between September 10, 2015, and January 31, 2019. In
October 2018, the IDMC recommended increased re-
cruitment from 132 to 150 randomly assigned patients to
address drop out. One hundred and fifty patients from 21
United Kingdom institutions (Data Supplement) were
randomly assigned with 75 per arm (ITT population, Fig 1).
At data cutoff (December 9, 2019), five patients (3.3%)
were still receiving capivasertib or placebo (to date, par-
ticipants remain blinded and without treatment crossover),
with none still receiving DP. Median follow-up, for all pa-
tients was 23.7 months (reverse Kaplan-Meier method,
interquartile range [IQR], 14.4-31.0; capivasertib arm 22.6
Journal of Clinical Oncology 3
Capivasertib and Docetaxel in mCRPC
Downloaded from ascopubs.org by University of Glasgow Library on January 5, 2021 from 130.209.116.071
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
(IQR, 15.6-29.9); placebo arm 23.7 (IQR, 14.4-32.1); Data
Supplement) and for patients still alive was 16.8 months
(IQR, 12.0-26.5). Table 1 shows baseline characteristics by
treatment allocation.
The safety population comprised 74 patients per arm, with
72 (96.0%) and 73 (97.3%) receiving at least one dose of
capivasertib or placebo, respectively. A median of seven
(IQR, 5-10) DP treatment cycles were administered with
medians of six (IQR, 4-10) in the capivasertib arm and
seven (IQR, 5-9) for placebo. Patients received a median of
17.7 weeks (IQR, 6.6-39.3) of capivasertib and 23.7 weeks
(IQR, 14.7-36.7) of placebo, with 14 (18.7%) and 13
(17.3%) having at least one dose reduction, respectively.
Data Supplement shows treatment duration, reductions,
and delays.
For the primary PFS ITT analysis there were 135 events,
with 67 (89.3%) in the capivasertib arm and 68 (90.7%)
for placebo. PFS events were by PSA progression in 55
(82.1%) and 55 (80.9%), respectively. Addition of
capivasertib to DP did not lower risk of progression
or death, with an adjusted HR of 0.92 (80% CI, 0.73
to 1.16, one-sided P 5 .32, Fig 2, Data Supplement).
Median PFS was 6.7 months (95% CI, 5.52 to 7.36) in
the placebo arm and 7.03 months (95% CI, 6.28 to
8.25) in the capivasertib arm. The 6-month PFS rate
was 56% and 62% in the placebo and capivasertib
cohorts, respectively.
For the OS secondary end point, there were 72 events
(48.0%), with 30 (40.0%) deaths in the capivasertib arm
and 42 (56.0%) for placebo. The predominant cause of
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FIG 1. CONSORT diagram. DP, docetaxel and prednisolone; EOS; end of study; ITT, intent to treat.
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TABLE 1. Baseline Characteristics
Characteristic DP Plus Capivasertib (n 5 75) DP Plus Placebo (n 5 75) Total (N 5 150)
Age, years
Mean (SD) 68.3 (6.79) 70.0 (6.05) 69.2 (6.46)
Median (IQR) 69 (64-67) 70 (66-75) 69 (65-74)
Range 50.0-84.0 55.0-82.0 50.0-84.0
Eastern Cooperative Oncology Group performance status
0 44 (58.7%) 46 (61.3%) 90 (60.0%)
1 31 (41.3%) 29 (38.7%) 60 (40.0%)
Pain score at baselinea
Range 0-9 0-8 0-9
Median 1 1 1
IQR 0-3 0-3 0-3
Opioid use at baseline
Yes 17 (22.7%) 19 (25.3%) 36 (24.0%)
No 58 (77.3%) 56 (74.7%) 114 (76.0%)
Time from prostate cancer diagnosis
Median, years 4.5 4.4 4.4
IQR 2.8-8.5 2.2-8.6 2.6-8.5
Sites of metastatic disease
Bone 61 (81.3%) 63 (84.0%) 124 (82.7%)
Lymph (pelvic and/or extrapelvic) 37 (49.3%) 32 (42.7%) 69 (46.0%)
Lung 5 (6.7%) 9 (12.0%) 14 (9.3%)
Liver 3 (4.0%) 5 (6.7%) 8 (5.3%)
Other 2 (2.7%) 6 (8.0%) 8 (5.3%)
Visceral (nonlymph node) metastatic disease
Present 14 (18.7%) 17 (22.7%) 31 (20.7%)
Not present 61 (81.3%) 58 (77.3%) 119 (79.3%)
Prior treatment with abiraterone or enzalutamide
Enzalutamide only 28 (37.3%) 25 (33.3%) 53 (35.3%)
Abiraterone only 18 (24.0%) 18 (24.0%) 36 (24.0%)
Both 5 (6.7%) 7 (9.3%) 12 (8.0%)
Neither 24 (32.0%) 25 (33.3%) 49 (32.7%)
Prior radical radiotherapy for prostate cancer
Yes 29 (38.7%) 27 (36.0%) 56 (37.3%)
No 46 (61.3%) 48 (64.0%) 94 (62.7%)
Prior radical prostatectomy
Yes 13 (17.3%) 7 (9.3%) 20 (13.3%)
No 62 (82.7%) 68 (90.7%) 130 (86.7%)
Gleason score
7 or less 21 (28.0%) 29 (38.7%) 50 (33.3%)
8-10 51 (68.0%) 40 (53.3%) 91 (60.7%)
Not recorded 3 (4.0%) 6 (8.0%) 9 (6.0%)
PSA, mg/L
Median (IQR) 37.5 (13.6-93.9) 62.0 (28.0-151.0) 46.5 (16.6-116.0)
(continued on following page)
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death was prostate cancer in 25 (83.3%) and 38 (90.5%) in
the capivasertib and placebo cohorts, respectively. Addi-
tion of capivasertib to DP resulted in a 46% reduction in
overall risk of death, with an adjusted HR of 0.54 (95% CI,
0.34 to 0.88, two-sided P5 .01, Fig 2, Data Supplement). A
difference in median OS of 10.9 months was shown, from
20.27 months (95% CI, 17.51 to 24.18) in the placebo
cohort to 31.15months (95%CI, 20.07, not reached) in the
capivasertib cohort, and 24-month OS rates of 39% versus
56%, respectively.
One hundred and thirty-six (90.7%) of the ITT population
were included within the biomarker population analysis. Of
these, 98 (72.1%) had an archival tissue biomarker result
(IHC and/or NGS); and 130 (95.6%) a baseline ctDNA NGS
result. Forty-four (32.4%) were biomarker-positive. Con-
sistent with previous data sets, PTEN alterations were the
predominant pathway alteration (36.5% PTEN deficiency
by IHC; 24% and 11% alterations by NGS in tissue and
plasma, respectively).20-23 Figure 3 and Data Supplement
show the contribution of the components to biomarker
status by patient. PFS and OS results were found to be
consistent irrespective of PI3K/AKT/PTEN pathway
activation status based on this biomarker (Table 2).
Analysis of PFS and OS with respect to individual com-
ponents of this composite biomarker, and a sensitivity
analysis including the ITT population, produced similar
results (Data Supplement). Forest plot analysis for strati-
fication factors used in random assignment and baseline
characteristics are shown in Figure 4 with respect to PFS
and OS.
PSA response rates were not different between treatment
arms with 45% (95% CI, 34% to 57%) and 55% (95% CI,
44% to 66%) having a PSA response in the capivasertib
and placebo cohorts, respectively (odds ratio, 0.66; 95%
CI, 0.35 to 1.26, P5 .207). Waterfall plots of PSA response
to week 12, and to best response, are provided in the Data
Supplement. Within the ITT population, PFS excluding PSA
progression alone and PSA-based PFS (and exploratory
analyses excluding new antiprostate cancer treatment as
events) were similar to those for the PFS primary end point
with outcomes not different by treatment arm (Supple-
mentary Tables 8-15, online only). No differences were
seen between treatment arms for bone pain up to treatment
cycle 5.
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FIG 2. Kaplan-Meier estimates by treatment arm for progression-free survival and overall survival in the intent-to-treat population.
TABLE 1. Baseline Characteristics (continued)
Characteristic DP Plus Capivasertib (n 5 75) DP Plus Placebo (n 5 75) Total (N 5 150)
Range 3.3-1,405.0 1.2-1,035.0 1.2-1,405.0
Lactate dehydrogenase above ULN 19 (25.3%) 24 (32.0%) 43 (28.7%)
Alkaline phosphate above ULN 28 (37.3%) 33 (44.0%) 61 (40.7%)
Albumin below LLN 7 (9.3%) 9 (12.0%) 16 (10.7%)
Hemoglobin below LLN 41 (54.7%) 46 (61.3%) 87 (58.0%)
Abbreviations: DP, docetaxel and prednisolone; IQR, interquartile range; LLN, lower limit of normal according to the local institutional range; PSA, prostate-
specific antigen; SD, standard deviation; ULN, upper limit of normal according to the local institutional range.
aPain in the 24 hours before baseline visit, on a scale from 0-10 (brief pain inventory).
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Within the safety population (74 per arm), every patient had
at least one adverse event, and 46 (62.2%) in both arms
had at least one grade $ 3 adverse event. Adverse events
leading to treatment discontinuation occurred in 17 pa-
tients (23.0%) in the capivasertib arm and in eight (10.8%)
placebo (Data Supplement), with at least one adverse event
assessed as related to capivasertib/placebo reported in 60
(81.1%) patients in the capivasertib arm and in 58 (78.4%)
in the placebo arm (Data Supplement). There were no
grade 5 adverse events, and a Mann-Whitney U test ex-
ploring the worst CTCAE grade for each patient showed no
significant differences between arms (P 5 .691). Table 3
shows adverse events, regardless of causality.
DISCUSSION
To the best of our knowledge, this is the first study to test
AKT inhibition combined with chemotherapy in prostate
cancer. Addition of capivasertib to DP did not extend the
composite primary end point of PFS used in this study in
mCRPC.
Intriguingly, however, we have detected a substantial in-
crease in the OS secondary end point. Data from this study
do not provide a definitive explanation for why the addition
of capivasertib to chemotherapy might extend OS but not
PFS. Furthermore, PSA response rates, although not sta-
tistically significantly different, favored the placebo arm
numerically, and survival outcomes were found to be
consistent irrespective of PI3K/AKT/PTEN pathway acti-
vation status.
Progression events occurred primarily through PSA pro-
gression in . 80% of patients in each arm. PSA level and
kinetics are a function of both total androgen receptor (AR)
function and disease bulk. One could hypothesize that
therapeutic combinations, where neither drug has an AR-
directed mechanism, might not impact a PSA-driven PFS
end point, at least to the same extent as treatments tar-
geting AR function directly. However, examples of non–AR-
directed therapy have previously impacted PSA based end
points.6,7 Preclinical data indicate that reciprocal crosstalk
mechanisms exist between PI3K/AKT/PTEN pathway sig-
naling and AR signaling in PTEN-deficient prostate cancer,
such that AKT inhibition might potentially increase AR
transcriptional activity and thus PSA expression.24 Poten-
tially, AKT inhibition might alter response to future thera-
pies, or alter patterns of progression rate or metastatic site.
TABLE 2. PFS and Overall Survival With Respect to Primary Biomarker Status
Outcome Median Capivasertib (Months) (95% CI) Median Placebo (Months) (95% CI) HR (95% CI) P
PFS 7.03 (6.28 to 8.25) 6.7 (5.52 to 7.36) 0.92 (0.65 to 1.31) .32
PFS, biomarker-positive (n 5 44) 7.75 (6.44 to 9.63) 7.98 (5.09 to 9.82) 1.17 (0.61 to 2.23)
PFS, biomarker-negative (n 5 92) 7.03 (4.21 to 8.25) 6.34 (4.76 to 7.13) 0.89 (0.57 to 1.37)
OS 31.15 (20.07 to NR) 20.27 (17.51 to 24.18) 0.54 (0.34 to 0.88) .01
OS, biomarker-positive 26.87 (14.59 to NR) 20.27 (12.91 to 35.71) 0.62 (0.26 to 1.47)
OS, biomarker-negative 32.43 (18.5 to NR) 20.30 (16.82 to 24.18) 0.54 (0.30 to 0.99)
NOTE: PFS (primary end point) has a one-sided P-value with a corresponding 80% CI for the HR of 0.73-1.16. The P-value for OS is two-sided.
Abbreviations: HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free survival.
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We designed ProCAID at a time when radiographic PFS was
a relatively uncommon end point in prostate cancer trials.
We recommend future investigation of AKT inhibition
should incorporate this end point, excluding PSA from the
end point definition.
We acknowledge the possibility that our results, indicating
an OS extension despite no PFS impact, might be spurious
and are challenging to explain. In addition, the OS data
remain relatively immature at this planned primary analysis.
Although the size of the OS benefit observed is enticing, the
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possibility that biases, whether identifiable or not, might
have impacted our results should be recognized. Sup-
porting this, we acknowledge some imbalances in
baseline patient characteristics that might have favored
the capivasertib arm outcome including rates of lung or
liver involvement, prior prostatectomy, median PSA, and
levels of lactate dehydrogenase, albumin, and alkaline
phosphatase (although conversely, good performance
status and high Gleason score rates might favor the
placebo arm).
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Prior data, from placebo-controlled phase II studies, sup-
port therapeutic targeting of the PI3K/AKT/PTEN pathway
in this and other cancers. Heterogeneity exists, however, in
patterns of benefit shown for PFS or OS, and outcomes of
biomarker subset analysis. In prostate cancer, de Bono et al
tested the pan-AKT inhibitor ipatasertib combined with
abiraterone versus abiraterone alone. Radiographic PFS
was extended in a subset with tumors exhibiting PTEN
protein expression loss by IHC. OS was not extended,
potentially through data immaturity, in distinction to the
result presented here.25 Capivasertib combinations also
have activity in breast cancer. In FAKTION, addition of
TABLE 3. Adverse Events, Irrespective of Causality, Occurring in More Than 10% of Patients in Either Treatment Arm Within the Safety Population
Capivasertib (n 5 74) Placebo (n 5 74) Total (N 5 148)
Adverse Event Grade ‡ 3 All Grades Grade ‡ 3 All Grades Grade ‡ 3 All Grades
Diarrhea 49 (66.2%) 5 (6.8%) 44 (59.5%) 3 (4.1%) 93 (62.8%) 8 (5.4%)
Fatigue 42 (56.8%) 1 (1.4%) 46 (62.2%) 1 (1.4%) 88 (59.5%) 2 (1.4%)
Nausea 25 (33.8%) 1 (1.4%) 26 (35.1%) 2 (2.7%) 51 (34.5%) 3 (2%)
Alopecia 26 (35.1%) — 24 (32.4%) — 50 (33.8%) —
Neuropathy peripheral 15 (20.3%) — 29 (39.2%) 2 (2.7%) 44 (29.7%) 2 (1.4%)
Constipation 16 (21.6%) — 26 (35.1%) 1 (1.4%) 42 (28.4%) 1 (0.7%)
Back pain 19 (25.7%) 5 (6.8%) 23 (31.1%) 2 (2.7%) 42 (28.4%) 7 (4.7%)
Dyspnea 18 (24.3%) 1 (1.4%) 22 (29.7%) 2 (2.7%) 40 (27%) 3 (2%)
Neutropenia 23 (31.1%) 19 (25.7%) 16 (21.6%) 14 (18.9%) 39 (26.4%) 33 (22.3%)
Taste disorder 15 (20.3%) — 16 (21.6%) — 31 (20.9%) —
Cough 16 (21.6%) — 14 (18.9%) — 30 (20.3%) —
Rasha 25 (33.8%) 7 (9.5%) 5 (6.8%) 1 (1.4%) 30 (20.3%) 8 (5.4%)
Vomiting 14 (18.9%) 1 (1.4%) 14 (18.9%) 1 (1.4%) 28 (18.9%) 2 (1.4%)
Decreased appetite 13 (17.6%) — 14 (18.9%) — 27 (18.2%) —
Lethargy 14 (18.9%) 2 (2.7%) 13 (17.6%) 1 (1.4%) 27 (18.2%) 3 (2%)
Nail disorder 8 (10.8%) — 18 (24.3%) — 26 (17.6%) —
Edema 12 (16.2%) — 13 (17.6%) — 25 (16.9%) —
Pyrexia 15 (20.3%) 5 (6.8%) 10 (13.5%) 5 (6.8%) 25 (16.9%) 10 (6.8%)
Dysgeusia 10 (13.5%) — 15 (20.3%) — 25 (16.9%) —
Arthralgia 8 (10.8%) — 15 (20.3%) 1 (1.4%) 23 (15.5%) 1 (0.7%)
Mucosal inflammation 14 (18.9%) 1 (1.4%) 8 (10.8%) 1 (1.4%) 22 (14.9%) 2 (1.4%)
Pain in extremity 9 (12.2%) — 12 (16.2%) 2 (2.7%) 21 (14.2%) 2 (1.4%)
Anemia 12 (16.2%) 1 (1.4%) 8 (10.8%) 4 (5.4%) 20 (13.5%) 5 (3.4%)
Lower respiratory tract infection 14 (18.9%) 2 (2.7%) 6 (8.1%) — 20 (13.5%) 2 (1.4%)
Urinary tract infection 7 (9.5%) — 13 (17.6%) — 20 (13.5%) —
Abdominal pain 9 (12.2%) — 10 (13.5%) — 19 (12.8%) —
Insomnia 7 (9.5%) — 12 (16.2%) — 19 (12.8%) —
Febrile neutropenia 11 (14.9%) 11 (14.9%) 6 (8.1%) 5 (6.8%) 17 (11.5%) 16 (10.8%)
Dry skin 9 (12.2%) — 8 (10.8%) — 17 (11.5%) —
Flushing 9 (12.2%) — 7 (9.5%) — 16 (10.8%) —
Dyspepsia 10 (13.5%) — 5 (6.8%) — 15 (10.1%) —
Musculoskeletal pain 8 (10.8%) — 6 (8.1%) — 14 (9.5%) —
Headache 5 (6.8%) — 8 (10.8%) — 13 (8.8%) —
Lacrimation increased 9 (12.2%) — 2 (2.7%) — 11 (7.4%) —
Groin pain 8 (10.8%) 1 (1.4%) 1 (1.4%) — 9 (6.1%) 1 (0.7%)
NOTE: There were no grade 5 treatment-related adverse events.
aRash is a grouped term for different descriptions of rash.
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capivasertib to fulvestrant extended PFS in ER-positive,
HER2-negative, advanced breast cancer. Effect size was
not altered by biomarker status for a composite of PIK3CA
alteration in either tumor or ctDNA, or PTEN protein ex-
pression loss in tumor.26 In PAKT, capivasertib combined
with paclitaxel in metastatic triple-negative breast cancer
extended both PFS and OS, and this effect was more
pronounced for tumors with PIK3CA, AKT1, or PTEN al-
terations.27 However, in BEECH, the same combination did
not extend PFS in ER-positive, HER2-negative, breast
cancer, irrespective of biomarker status for PIC3CA alter-
ations. Of note, no concomitant or maintenance endocrine
therapy was allowed during this study.28 The significance of
variations across these data sets for disease type, drug
combination partner, and biomarker composition remains
to be determined and suggest that benefit and the required
patient selection approach may be context-dependent.
Randomized phase II data for capivasertib combined
with the AR antagonist enzalutamide for mCRPC are
awaited from the ongoing RE-AKT trial.29
Consistent with our prior data, addition of capivasertib to DP
resulted in an acceptable toxicity profile.16 A significant
proportion of adverse events recorded were primarily
chemotherapy or disease-related. Of those events desig-
nated as capivasertib (or placebo)-related, an excess in
rash, diarrhea, fatigue, and nausea occurred in the cap-
ivasertib arm. These adverse events are expected for
capivasertib and common across PI3K and AKT inhibi-
tors and warrant consideration of mitigation strategies in
future development of this combination. Prednisolone,
as a conventional component of DP for mCRPC, in ad-
dition to dexamethasone premedication, did not appear
to drive excess of toxicity relating to transient hypergly-
cemia seen with capivasertib. No cases of hyperglycemia
required intervention or triggered protocol defined cri-
teria for use of metformin.
In conclusion, capivasertib did not extend PFS when
combined with DP for mCRPC irrespective of PI3K/
AKT/PTEN pathway activation status. We found a
statistically significant extension in the secondary end
point of OS. To address the apparent discordance in
this result would require prospective validation studies
that should focus on identification of patients most
likely to benefit.
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